Tricaprilin not checked
Cerecin · AC-SD-03 · AC-OL-01
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Each dose of IMP will be administered orally 30 minutes after completing a full meal. There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA. Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 2-4 weeks.”In the company’s words, NCT05809908 on ClinicalTrials.gov
- Tested for
- Alzheimer Disease
- Main trialPhase 3
- “The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.”In the company’s words, NCT05809908 on ClinicalTrials.gov
- Other names
- AC-SD-03 · AC-OL-01 · AC-1204 · AC-1202
Other drugs for Alzheimer Disease
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up1
- Jan 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Jan 2030 | Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study | |
| Phase 3Withdrawn | 31 Dec 2023 | A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension | |
| Phase 2/3Completed | 24 Oct 2016 | AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext | |
| Phase 2Completed | 7 Feb 2022 | Tricaprilin Phase 2 Pilot Study in Migraine | |
| Phase 1Terminated | 18 Mar 2022 | Tricaprilin Liquid Formulation PK Study | |
| Phase 1Completed | 4 Dec 2023 | Tricaprilin Infantile Spasms Pilot Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026